ArticleNature immunology2021
Dynamic CD4
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Stepwise differentiation from precursor intermediates and distinct Th1 checkpoints promote CD4 Th1 cell differentiation during chronic viral infection.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Stem-like CD4 T cells in tumors: an emerging framework for antitumor immunity.Frontiers in immunology · 2026Review
- Macrophage plasticity in thyroid eye disease: dual effects of inflammation and fibrosis.Frontiers in immunology · 2026Review
- PD-1 expressing islet-specific CD4Immunology and cell biology · 2025Article
- The role of the PD-1/PD-L1 immune checkpoint pathway in myocardial infarction: a review from pathophysiological mechanisms to therapeutic strategies.Frontiers in cardiovascular medicine · 2025Review
- Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- CAF-induced physical constraints controlling T cell state and localization in solid tumours.Nature reviews. Cancer · 2024Review
- PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.Frontiers in immunology · 2024Article
- A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity.Science translational medicine · 2023Article
- Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control.Cell reports · 2023Article
- T cells in health and disease.Signal transduction and targeted therapy · 2023Review
- Exhausted CD8Trends in immunology · 2023Review
- CD4Nature cancer · 2023Review
- Population dynamics and gene regulation of T cells in response to chronic antigen stimulation.International immunology · 2023Review
- A viral-specific CD4Frontiers in immunology · 2023Article
- The transcription factor IRF2 drives interferon-mediated CD8Immunity · 2022Article
- Article
- Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.Nature immunology · 2022Article
- A CD4eLife · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 2 countries.
Funding
Abstract
Inhibiting PD-1:PD-L1 signaling has transformed therapeutic immune restoration. CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.